Company
CFO
9 appearances
Latest appearance 2026-03-10
Benjamin Halladay
CFO
Analyst
Intern, Finance Department
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Benjamin Halladay
Benjamin Halladay is recorded as Analyst at Intern, Finance Department. The company reported in an 8-K filed November 16, 2022 that Benjamin Halladay was appointed Chief Financial Officer, effective November 16, 2022. The proxy statement of the company reports total compensation of $1,351,935 for Benjamin Halladay in fiscal 2025, including a base salary of $495,833. Disclosed compensation is on record for 2 fiscal years. Benjamin Halladay has spoken on 9 earnings calls across 1 company, most recently on March 10, 2026.
“On November 16, 2022, the board of directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) appointed Benjamin Halladay as the Company’s Chief Financial Officer pursuant to the terms of an employment agreement with Mr. Halladay (the “Halladay Agreement”), effective as of November 16, 2022 (the “Commencement Date”).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Organization not stated
CFO
Proxy statement
CurrentStart not stated–present
-
Intern, Finance Department
Analyst
Source not stated
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | — | Chief Financial Officer | $495,833 | $1,351,935 |
| 2024 | — | Chief Financial Officer | $467,333 | $1,368,427 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
-
Earnings call
Esperion Therapeutics, Inc. Q4 FY2025 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q3 FY2025 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q2 FY2025 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q4 FY2024 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q1 FY2024 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q4 FY2023 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q2 FY2023 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q1 FY2023 Earnings Call
-
Earnings call
Esperion Therapeutics, Inc. Q4 FY2022 Earnings Call
-
Executive change Appointed: Chief Financial Officer